{"id":"NCT02545517","sponsor":"GlaxoSmithKline","briefTitle":"A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.","officialTitle":"A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults Who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis With Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately From a Japanese Encephalitis Vaccine.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-05","primaryCompletion":"2022-12-23","completion":"2022-12-23","firstPosted":"2015-09-10","resultsPosted":"2024-07-18","lastUpdate":"2024-07-18"},"enrollment":459,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Virus Diseases","Rabies"],"interventions":[{"type":"BIOLOGICAL","name":"Rabipur","otherNames":[]},{"type":"PROCEDURE","name":"Blood sampling","otherNames":[]},{"type":"BIOLOGICAL","name":"Purified Chick-Embryo Cell Rabies Vaccine","otherNames":[]}],"arms":[{"label":"Conv-R/JE Group","type":"EXPERIMENTAL"},{"label":"Acc-R/JE Group","type":"EXPERIMENTAL"},{"label":"Conv-R Group","type":"EXPERIMENTAL"}],"summary":"The aim of this study is to evaluate the long-term (up to approx.10 years) persistence and to assess the boostability of immune responses in participants who received a primary series of accelerated or conventional rabies PrEP IM regimen.\n\nThis product has been transferred to BN. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on www.clinicaltrials.gov.","primaryOutcome":{"measure":"Number of Participants Reporting Serious Adverse Events (SAEs) After a Booster Dose of Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine","timeFrame":"From booster vaccination [6 to 9 months after Year 3 (3 years after primary series of vaccination)] up until completion of the safety follow-up period (10 years after primary series of vaccination)","effectByArm":[{"arm":"Conv-R/JE Group","deltaMin":2,"sd":null},{"arm":"Acc-R/JE Group","deltaMin":0,"sd":null},{"arm":"Conv-R Group","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":7,"countries":["Austria","Germany","Switzerland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":44},"commonTop":[]}}